The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
News|Slideshows|May 8, 2019
Type 2 Diabetes: After the Diagnosis, Resist Inertia
Author(s)Susan E Williams, MS, RD, MD
Diabetes is a progressive disease and takes advantage of inaction. How would you manage our patient Mrs Davis?
Advertisement
After a diagnosis of type 2 diabetes, clinician and patient alike are challenged to keep pace with and, ideally stay ahead of, the progressive Ã-cell deterioration that underlies diabetes pathophysiology. Find out how Mrs Davis and her doctor get started.
Advertisement
Related to this article
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Advertisement
Advertisement
Trending on Patient Care Online
1
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
2
FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
5